Applying CPT and HCPCS C-Codes and Rules for Drug Administration Services to Clinical Scenarios
|
|
- Lily Underwood
- 6 years ago
- Views:
Transcription
1 Applying CPT and HCPCS C-Codes and Rules for Drug Administration Services to Clinical Scenarios
2 IMPORTANT PLEASE READ The information provided in this handout is informational only and should not be taken as an official answer of how to report codes and units for the services described in these clinical scenarios. Our audioconference speakers have provided this in an attempt to help hospitals sort through a number of drug administration reporting issues, but each hospital must make its own determination of how to report these services to Medicare and non-medicare payers. If you are confused or disagree, we urge you to request guidance from your FI and CMS. We cannot provide any further information or explanations at this time. If you have further questions, please contact Nimitt Consulting at jugna@nimitt.com to engage consulting services.
3 Answer for Clinical Example 1: Emergency Department Visit for a Gastric Ulcer Patient ED Visit Example 2006 CPT Codes for non- Medicare use 2006 HCPCS C- codes for Medicare Use Service Time Explanation 2006 Codes 2006 Codes IVP 14:00 Protonix x 1 C8952 x 1 IVP 14:10 Demoral x 1 C8952 x 1 IVP 14:15 Ativan x 1 C8952 x 1 ED Visit ED Level III x x 1 Page 1
4 Answer for Clinical Example 2: Emergency Department and Observation Visit for a Gastric Ulcer Patient ED and Observation Example 2006 CPT Codes for non- Medicare use 2006 HCPCS C- codes for Medicare Use Service Time Explanation 2006 Codes 2006 Codes IVP 14:00 Protonix x 1 C8952 x 1 IVP 14:10 Demoral x 1 C8952 x 1 IVP 14:15 Ativan x 1 C8952 x 1 ED Visit ED Level III x x 1 Observation 14:30-16:30 Admit to Obs x 2 G0378 x 2 Infusion started in Observation 14:30-16:30 Therapeutic Infusion x x 1 C8950 x 1 C8951 x 1 IVP 16:30 Dilaudid x 1 C8952 x 1 Page 2
5 Answer for Clinical Example 3: Multiple Push Injections of the Same Drug Chemo Regimen 2005 Hospital Reporting 2005 CPT 2006 C- Service Time Explanation Codes 2006 CPT Codes Codes IVP Lasix x x 1 C8952 x 1* IVP Lasix x 1 IVP Lasix x 1 IVP Lasix x CPT Codes for non- Medicare use 2006 HCPCS C-Codes for Medicare Use
6 Answer for Clinical Example 4: Concept of Concurrent Drug and CMS Administration as Presented at the CPT Symposium in Chicago 2006 CPT Codes Service Time Explanation for non- Medicare use 2006 C-Codes for Medicare Use IVPB Antibiotic x 1 C8950 x1 IVPB Antibiotic x 1 No Medicare C-code available to report concurrent infusion IVP Phenrgan x 1 C8952 x 1 This is the answer presented by physicians at the CPT meeting in Chicago. We believe that there is no way to report the second antibiotic infusion on the Medicare side given that there is no code available and also because both infusions are of the same type. If the concurrent infusion was of a different type (i.e., a chemotherapy drug infusion), then we believe guidance from Transmittal 785 would allow us to report Page 4 both the antibiotic and the chemo infusion.
7 Answer for Clinical Example 5: Two Chemotherapy Push Drugs with a Non-Chemotherapy Drug Two Different Chemo Drugs Given IVP and Non- Chemo by IVP 2006 CPT Codes Non-Medicare Use 2006 CPT and HCPCS C-codes for Medicare Use Service Time Explanation 2006 Codes 2006 codes IVP 9:00 PS-341 (chemo) x 1 C8953 x 1 IVP 10:02 5FU (chemo) x 1 C8953 x 1 IVP 9:30 Leucovorin (nonchemo) x 1 C8952 x 1 Page 5
8 Answer to Clinical Example 6: Chemotherapy Infusion with Anti-Emetics Chemo Regimen 2006 CPT Codes for Non-Medicare use 2006 HCPCS C-codes for Medicare Use Service Time Explanation 2006 Codes 2006 Codes Decadron/Aloxi (nonchemo) C8952 x x 1 IVP 10:00-10:10 1 IVP 10:10-10:20 Reglan (non-chemo) x 1 C8952 x 1 IV infusion 12:20-14:20 Cisplatin (chemo) x x 1 C8954 x 1 C8955 x 1 Page 6
9 Answer to Clinical Example 7: Chemotherapy Infusion with Anti-Emetics, Pre-and- Post Hydration, and Additional Meds Chemo Regimen 2006 CPT Codes for non- Medicare use 2006 C-codes for Medicare Use Service Time Explanation 2006 Codes 2006 Codes Decadron/Aloxi (nonchemo) C8952 x x 1 IVP 10:00-10:10 1 IVP 10:10-10:20 Reglan (non-chemo) x 1 C8952 x 1 IV infusion 10:20-12:20 Hydration x 2 C8950 x 1 C8951 x 1 IV infusion 12:20-14:20 Cisplatin (chemo) x x 1 C8954 x 1 C8955 x 1 IVP 14:20-14:55 Mannitol (non-chemo) x 1 C8952 x 1 IV infusion 14:55-16:55 Hydration x 2 C8951 x 2 IV infusion 16:55-17:55 Etoposide (chemo) x 1 C8955 x 1 IVP 17:55-18:05 Bleomyocin (chemo) x 1 C8953 x 1 Page 7
10 Answer to Clinical Example 8: Concept of Sequential Drug Administration as Presented at the CPT Symposium in Chicago Chemo Regimen 2006 CPT Codes for non- Medicare use 2006 HCPCS C- Codes for Medicare Use 2006 CPT Service Time Explanation Codes 2006 C-Codes IVP 9:00-9:20 Ativan (non-chemo) x 1 C8952 x 1 IVPB 9:25-9:45 Decadron, Zofran, Benadryl (non-chemo) x 1 C8950 x 1 IV Infusion 9:45-10:45 Paraplatin (chemo) x 1 C8954 x 1 IV Infusion 10:45-11:15 Cytoxan (chemo) x 1 N/A Note: There is no sequential chemotherapy infusion C-code available to report to Medicare. Also, the total time of the Paraplatin and Cytoxan does not meet the time requirement to bill any additional hours using the C8955 add-on code. Page 8
11 Answer for Clinical Example 9: Chemotherapy Infusion and Hydration with Overlapping Time Chemo Regimen w/ hydration hour overlapping with Chemo Infusion 2006 CPT Codes for non-medicare use 2006 HCPCS C-codes for Medicare Use Service Time Explanation 2006 CPT Codes 2006 codes IVP 13:15 (15 min) Zofran (non-chemo) x 1 C8952 x 1 IV infusion 13:15-16:45 Hydration x 3 OR see below C8950 x 1 C8951 x 2 or see below Codes/units if overlapping time for Cytoxan and Taxotere is deducted (hydration then = 45 minutes) x 1 C8950 X 1 IVP 13:25-13:55 Adriamycin (chemo) x 1 C8953 x 1 IV infusion 14:00-15:30 Cytoxan (chemo) x 1 C8954 x 1 IV infusion 15:30-16:30 Taxotere (chemo) x 1 C8955 x 1 Since the hydration runs throughout the course of the chemotherapy infusion, many hospitals are only reporting the non-overlapping hydration time and not the overlapping time (i.e., not the full duration of the hydration if it overlaps). Please request clarification from your FI and/or CMS. Page 9
12 Answer to Clinical Example # 10: Concept of Concurrent Infusions Under CPT Codes vs. Medicare C-Codes 2006 CPT Codes 2006 HCPCS C- for non-medicare codes for use Medicare Use Service Time Explanation 2006 CPT Codes 2006 Codes SAMPLE FOLFOX REGIMEN Chemotherapy drug infusion 10:00 to 12:00 The drug Oxaliplatin is infused concurrently with the non-chemo Leucovorin drug through "Y" tubing. Oxaliplatin is compatible with Leucovorin, but not the second chemo drug Fluorouracil. Order reads: Oxaliplatin 85mg/m2 IVPB Run in 2 hrs x x 1 C8954 x 1 C8955 x 1 Nonchemotherapy drug infusion 10:00 to 12:00 The non-chemo drug Leucovorin is infused concurrently with the chemo drug Oxaliplatin through "Y" tubing. Order reads: Leucovorin 200mg/m2 IVPB run in 2 hrs.mg/m2 IVPB Run in 2 hrs x 1 C8950 x 1 C8951 x 1 Chemotherapy drug injection 12:10 Fluorouracil given by the hospital as an IVP x 1 C8953 x 1 There is no concurrent infusion C-code for Medicare. However, in this example, two different types of services are running concurrently (chemo and non-chemo). We believe Transmittal 785 allows for both of these services to be reported. The concept of concurrent is not well-defined, therefore hospitals should request clarification from their FI and/or CMS to determine how they will report this. We have requested official guidance but have not received a response as of Feb 3, Page 10
Infusion Coding Infusions, Pushes, Injections
Infusion Coding Infusions, Pushes, Injections Presented by: Annalynn Hall, M.Ed, CPC, CHONC 1 Codes The codes used in this presentation are copyrighted by the AMA Review all codes and code descriptions
More informationOutpatient Infusion Coding & Documentation: Take Your Skills to a Higher Level
Outpatient Infusion Coding & Documentation: Take Your Skills to a Higher Level Presented by Robin Zweifel, BS, MT(ASCP) Marta Kramer, MBA, CCS-P.. June 27, 2014 Disclaimer MedLearn Publishing has prepared
More informationBILLING & CODING MEDICAL ONCOLOGY. Risë Marie Cleland, Oplinc Inc. June 2017
BILLING & CODING MEDICAL ONCOLOGY Risë Marie Cleland, Oplinc Inc. June 2017 CPT is a Registered Trademark of the AMA CPT copyright 2017 American Medical Association. All rights reserved. Fee schedules,
More informationBilling for Infusion Services in an Outpatient Neurology Clinic. Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute
Billing for Infusion Services in an Outpatient Neurology Clinic Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute Overview of Infusion Billing Codes Current Procedure Terminology
More informationType Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily
Colorectal - Adjuvant Standard adjuvant therapy for Duke's C Day(s) Drug Dose Route Comments and high risk Duke's B Colorectal cancer 5-FU/FA Weekly 1 Folinic acid 50mg IV IV Bolus injection via fast running
More informationCoding Tips, Hints & Pointers for Medical Oncology Billing
Coding Tips, Hints & Pointers for Medical Oncology Billing Empire State Hematology & Oncology Society Meeting October 5, 2018 Disclaimer When a third party payer is involved, the determination of reimbursement
More informationInfusion Coding. Is this going to hurt? Presented by: Annalynn Hall, M.Ed, CPC, CHONC. Codes
Infusion Coding Is this going to hurt? Presented by: Annalynn Hall, M.Ed, CPC, CHONC 1 Codes The codes used in this presentation are copyrighted by the AMA Review all codes and code descriptions for appropriate
More informationDavis s Drug Guide Scavenger Hunt 15 th Edition
Davis s Drug Guide Scavenger Hunt 15 th Edition This handout is designed to assist you in locating information in the Davis s Drug Guide. Take advantage of the many resources in this text!! Locate the
More informationClinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119
Clinical Policy: (Cyramza) Reference Number: CP.PHAR.119 Effective Date: 05/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationPHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
DRUG AND TREATMENT Available at: ALL Adult Facilities Non Categorized SUB ED Abdominal Pain Protocol(SUB)* ***The above subphase is available at the end of the plan*** SUB ED Abdominal Pain Protocol Lab
More informationEnsuring Accuracy: Chargemaster and Outpatient Facility Coding
Ensuring Accuracy: Chargemaster and Outpatient Facility Coding Catrena L. Smith CCS, CCS-P, CPC, PCS Disclaimer This material is provided as education for coders and other personnel involved in the coding
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationCancer SLO Practice (online set) Page 1 of 5
Cancer SLO Practice (online set) Page 1 of 5 1. Aranesp is? A. Darbepoetin alfa B. Filgrastim C. Epoetin alfa D. Sargramostim E. Pegfilgrastim 2. BCNU is? B. Cyclophosphamide 3. Bleomycin is a natural
More information05/01/2014. Medicare has 4 parts A: Hospital coverage National Training Program. Session Objectives. The Basics. B: Outpatient medical coverage
2015 National Training Program Medicare Prescription Drug Coverage Parts A, B and D Session Objectives This session should help you Differentiate when/under what scenarios drugs are covered under the various
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationPerioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran
Perioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran Institute of Clinical Cancer Research Krankenhaus Nordwest UCT - University Cancer Center
More informationReporting Mammograms for Medicare Patients Coding these preventive procedures depends on the payer.
Reporting Mammograms for Medicare Patients Coding these preventive procedures depends on the payer. By Barbara Aubry, RN, CPC, CPMA, CHCQM, FABQAURP For 2017, the American Medical Association (AMA) deleted
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationIs There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?
Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationRe: Comprehensive Ambulatory Payment Classification Methodology
Tiffany Swygert Director, Division of Outpatient Care Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244-1850 Re: Comprehensive Ambulatory Classification Methodology
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More information亞東紀念醫院 Breast Cancer 化學治療處方集
亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,
More informationADULT Updated: September 4, 2018
Updated: September 4, 2018 Regimen Reference Order ARIA: LYMP [R-CHOP alt. R-DHAP] Planned Course: Indication for Use: Every 21 days for 6 cycles (R-CHOP given on cycles 1, 3 and 5; R-DHAP given on cycles
More informationGenomic Health, Inc. Oncotype DX Colon Cancer Assay Clinical Compendium March 30, 2012
Economic Validity Eligibility and Addressability for Use of the Assay An important distinction should be made between the total population of patients eligible for the Oncotype DX Colon Cancer assay, and
More informationMedicare Part C Medical Coverage Policy
Medicare Part C Medical Coverage Policy Oral Antiemetic Medications Origination: June 17, 2009 Review Date: May 17, 2017 Next Review: May, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Oral antiemetic medications
More informationCHEMOTHERAPY FOR METASTATIC GASTRIC CANCER
CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain
More informationOptimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles YES
Optimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles YES Bassel F. El-Rayes 1 Background Standard of care for resected stage III colon cancer is six months of adjuvant oxaliplatin-based therapy
More informationNCCN Chemotherapy Order Templates
USER GUIDE NCCN Chemotherapy Order Templates (NCCN Templates ) Access to the NCCN Chemotherapy Order Templates (NCCN Templates ) for non-commercial users is available via subscription. Prior to accessing
More informationONCOLOGY LETTERS 2: , 2011
ONCOLOGY LETTERS 2: 241-245, 2011 Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following
More informationOVERALL CLINICAL BENEFIT
cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
information aligned with the expected toxicity profile of panitumumab, which is well-known as panitumumab is already used as a third-line therapy for patients with mcrc. perc also noted QoL did not deteriorate
More informationChemotherapy of Breast Cancer
Japan - Taiwan Joint Symposium on Medical Oncology Session 7 Breast cancer journal homepage:www.cos.org.tw/web/index.asp Chemotherapy of Breast Cancer Mei-Ching Liu Department of Medicine, Koo Foundation
More informationC ODING PAIN C LINICS. After attending this presentation, attendee will be able to: Coding Check List
Home Town Health Take the Pain out of Coding Pain Clinics J E NAN C U S TER C P C, C C S, C D I P AH IMA A PPROVED IC D - 1 0 - C M/PC S T RAINER AND A MBASSADOR D IRECTOR OF C ODING H EALTHCARE C ODING
More informationNCCP Chemotherapy Regimen. FLOT Therapy-14 day
INDICATIONS FOR USE: FLOT Therapy-14 Regimen Code 00344a *Reimbursement Indicator INDICATION ICD10 Treatment of locally advanced ( T2) and/or nodal positive (N+) C16 resectable gastric adenocarcinoma Treatment
More informationTrends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness
More informationPanel Two: Evidence for Use of Maintenance Therapy
Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Erbitux) Reference Number: CP.PHAR.317 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationLisa M. Hess Diane Michael Daniel S. Mytelka Julie Beyrer Astra M. Liepa Steven Nicol
Gastric Cancer (2016) 19:607 615 DOI 10.1007/s10120-015-0486-z ORIGINAL ARTICLE Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective
More informationANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99)
ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99) CLASSIFICATION OF TREATMENT GROUPS: 1. Isolated Skin lesions, < 5 skin lesions. Treatment course: ( No treatment, wait and see approach)
More informationOncology Competency Self Assessment
Oncology Competency Self Assessment Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values confirm your
More informationPHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
Available at ALL facilities Non Categorized SUB ED Chest Pain: STEMI Protocol(SUB)* SUB ED Chest Pain: STEMI Protocol Lab Orders(SUB)* ED Rainbow Tubes(SUB)* ***Reminder: Order ED Rainbow Tubes (SUB) as
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationMP Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5- Flourouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer
MP 2.04.56 Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5- Flourouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer Medical Policy Section Medicine Issue 12:2013 Original
More information1-844-FAX-A360 ( )
1-844-ASK-A360 (1-844-275-2360) 1-844-FAX-A360 (1-844-329-2360) www.myaccess360.com For more information, call AstraZeneca Access 360 at 1-844-ASK-A360, Monday through Friday, 8 am to 8 pm ET. IMFINZI
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317
Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date:
Clinical Policy: (Erbitux) Reference Number: ERX.SPA.261 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationTo help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More informationPharmacy Management Drug Policy
11/13, 10/12, 11/11, 1, 6/10, Page 1 of 5 DESCRIPTION: Cetuximab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor
More informationSymptom Management. Thomas McKain, MD, ABFM, ABHPM Medical Director
Symptom Management Nausea & Vomiting Thomas McKain, MD, ABFM, ABHPM Medical Director Mr. Jones has nausea and vomiting. May I initiate Compazine from the Comfort Pak? Objectives 1. Delineate the Differential
More informationAuditors Desk Reference
Auditors Desk Reference 2016 Contents Chapter 1. Auditing Processes and Protocols... 1 Claims Reimbursement... 1 Role of Audits... 6 Medical Record Documentation... 9 Chapter 2. Focusing and Performing
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationInternational Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry. Types I, II and III PPB
CHILDREN S HOSPITALS AND CLINICS of MINNESOTA 2525 Chicago Avenue South Minneapolis, Minnesota 55404, USA International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry Types I, II and III
More informationReference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationTESTS AND MONITORING:
BC Cancer Protocol Summary for Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Radiation Therapy Protocol Code: GIEFFOXRT Tumour Group:
More informationCisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE:
Cisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE: Protocol INDICATION ICD10 Code Small cell lung cancer (SCLC) limited disease C34 00279a ELIGIBILTY: Indications as above ECOG 0-2
More informationInjectable Opioid Shortage: February 27, 2018
Injectable Opioid Shortage: February 27, 2018 Beginning approximately June 2017, the supply of hydromorphone injection started to become an issue across the U.S. due to demand exceeding supply per most
More informationResectable locally advanced oesophagogastric cancer
Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018
pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018 DISCLAIMER Not a Substitute for Professional Advice This
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationDisclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer
Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationPolicy. ( Number: *Pleasesee amendment forpennsylvaniamedicaidatthe endofthis CPB.
1 of 11 (https://www.aetna.com/) Number: 0889 Policy *Pleasesee amendment forpennsylvaniamedicaidatthe endofthis CPB. Aetna considers levoleucovorin (Fusilev) medically necessary for the following indications,
More informationIrinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer
Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal
More informationEloxatin (Oxaliplatin)
Policy Number ELO12012011RP Approved By UnitedHealthcare Medicare Committee Current Approval Date 09/10/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare
More informationPing-Tsung Chen, MD; Chuang-Chi Liaw, MD
Original Article 167 Intravenous Ondansetron plus Intravenous Dexamethasone with Different Ondansetron Dosing Schedules during Multiple Cycles of Cisplatin-based Chemotherapy Ping-Tsung Chen, MD; Chuang-Chi
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationPHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
DRUG AND TREATMENT Available at: ALL Adult Facilities Non Categorized SUB Protocol(SUB)* SUB Protocol Lab Orders(SUB)* ED Rainbow Tubes(SUB)* ***Reminder: Order ED Rainbow Tubes (SUB) as a separate form***
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationCisplatin and Vinorelbine and radiotherapy (NSCLC)
Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10
More informationPancreatic Cancer Where are we?
Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer
More informationCisplatin and Vinorelbine and radiotherapy (NSCLC)
Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10
More informationSymptom Management of Gastrointestinal Alterations
Symptom Management of Gastrointestinal Alterations Parisa Tsutsumi RN, BSN, OCN, BMTCN University of Washington Medical Center Nausea and Vomiting Mucositis Taste Alterations Gastrointestinal Alterations
More informationMEDICARE RECOVERY AUDIT CONTRACTORS
MEDICARE RECOVERY AUDIT CONTRACTORS RAC ROUND-UP SUBSCRIPTION SERVICE RACS: What Are We Learning? Newly Approved Issues: Part 2 September 1, 2009 2009 Aegis Compliance & Ethics Center, LLP 1 1 Faculty
More informationFluorouracil, Oxaliplatin and Docetaxel (FLOT)
Fluorouracil, Oxaliplatin and Docetaxel (FLOT) Indication Perioperative chemotherapy for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. ICD-10 codes Codes with a prefix C15,C16 Regimen
More informationMedicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services US Department of Health and Human Services Attention: CMS-1695-FC P.O. Box 8013, 7500 Security Boulevard Baltimore, MD 21244-1850
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationFront-line treatment in young. Role of maintenance therapy. Rome 2017 Prof Le Gouill S.
Front-line treatment in young patients with MCL: Role of maintenance therapy Rome 2017 Prof Le Gouill S. Is there a need for maintenance for young MCL patients? Is there a need for maintenance for young
More informationNausea and Vomiting. Symptom Management of Gastrointestinal Alterations. Gastrointestinal Alterations. Nausea/Vomiting Patterns
Symptom Management of Gastrointestinal Alterations Elise Frans, MN, RN, CWON Oncology Clinical Nurse Specialist University of Washington Medical Center delterzo@uw.edu Nausea and Vomiting Mucositis Taste
More informationCBC with Differential. PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
DRUG AND TREATMENT Non Categorized SUB ED Snakebite Protocol (SUB)* Non Categorized ***(NOTE)*** This plan is designed to be used as part of a larger plan, not independently. Please do NOT order individually.
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationCyramza (ramucirumab)
Cyramza (ramucirumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 03/01/2017TBD03/01/2018 POLICY A. INDICATIONS The indications
More information